Seeking Alpha

Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre ...

--Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated long-term safety and efficacy data from a ...
Seeking Alpha

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

– Demonstrated target engagement and response prediction for ALTO-203 by theta/beta ratio, a commonly used EEG index of cortical arousal and attentional control – – ALTO-203, a non-stimulant compound ...

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell ...

First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA ...
ascopubs.org

The FOxTROT platform: Clinical trials and exploratory research for personalization of neoadjuvant (NA) therapy in locally advanced colon cancer (LACC)—ISRCTN83842641.

The CIRCULATE Spain study: Circulating tumor DNA based decision for adjuvant treatment in localized colon cancer. PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for ...